Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders; however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Here we review the rationale for psilocybin-assisted psychotherapy as a potential treatment for this indication, and describe practical considerations based on our early experience designing and implementing four separate clinical trials of psilocybin-assisted psychotherapy for methamphetamine use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the open-label design must be considered, this suggests 25 mg psilocybin may occasion a potent psychedelic effect in people with dependent MA use [17].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The putative transdiagnostic potential of psilocybin-assisted psychotherapy to enhance cognitive and neuronal plasticity, which are commonly impaired in substance use disorder, make it a promising novel treatment for MAUD [17].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Synaptic plasticity and addiction
Kauer, J. A., & Malenka, R. C. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2234 · Cited by 1,397 · cited 1×
“Drugs with high addiction potential, like methamphetamine, can hijack neuroplastic mechanisms in key brain regions, such as the mesolimbic dopamine system, ultimately contributing to the maladaptive maintenance of addictive behavior (50).”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · cited 1×
“Lastly, psilocybin can occasion profound mystical-type experiences that mediate ratings of substantial personal meaning and spiritual significance (57, 60, 61).”
BackgroundBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628 · cited 2×
“Conversely, preclinical evidence suggests that psilocybin may induce neuroplasticity in the prefrontal cortex and hippocampus (24, 25), which could potentially be leveraged in the context of psychotherapy to facilitate extinction learning, long-term alterations in emotion processing and reward and stress processing, a…”
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Davidson, C., Gow, A. J., Lee, T. H., & Ellinwood, E. H. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00054-6 · Cited by 521
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · cited 2×
“The participant-reported strength of the psilocybin-occasioned mystical-type experience has also been strongly associated with reductions in alcohol use and tobacco cessation in clinical trials of psilocybinassisted psychotherapy for those indications (31, 62).”
BackgroundHan, D. D., & Gu, H. H. (2006) · BMC Pharmacology · doi:10.1186/1471-2210-6-6 · Cited by 419
Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults
Han, B., Compton, W. M., Jones, C. M., Einstein, E. B., & Volkow, N. D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2588 · Cited by 380 · cited 3×
“instance, there has been a 10-fold increase in methamphetamine use among African American individuals between 2015 and 2019, compared to a 3-fold increase among White individuals (9).”
BackgroundInfluentialDavis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · cited 1×
“Methamphetamine use disorder trials ought to explore these potential predictors too, alongside others, including brain network connectivity, attachment security (59), connectedness (87), psychological flexibility (88), and stress biomarkers such as inflammation, cortisol, and heart rate variability.”
BackgroundLappan, S. N., Brown, A. W., & Hendricks, P. S. (2020) · Addiction · doi:10.1111/add.14793 · Cited by 370
Brain default-mode network dysfunction in addiction
Zhang, R., & Volkow, N. D. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.036 · Cited by 363
The Methamphetamine Problem in the United States
Gonzales, R., Mooney, L., & Rawson, R. A. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103600 · Cited by 361 · cited 1×
“Moreover, people who use methamphetamine consistently demonstrate more challenges in treatment and recovery compared to those using other substances (16, 17).”
BackgroundJohnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Homer, B. D., Solomon, T. M., Moeller, R. W., Mascia, A., DeRaleau, L., & Halkitis, P. N. (2008) · Psychological Bulletin · doi:10.1037/0033-2909.134.2.301 · Cited by 304
Brecht, M.-L., & Herbeck, D. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.702 · Cited by 280
The use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Patterns and Characteristics of Methamphetamine Use Among Adults — United States, 2015–2018
Jones, C. M., Compton, W. M., & Mustaquim, D. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912a1 · Cited by 245 · cited 2×
“As such, evidence suggests that psilocybin-assisted psychotherapy could address various psychiatric conditions commonly comorbid with methamphetamine use (27), such as treatment-resistant depression and anxiety (37, 38).”
Backgroundvan Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581980 · Cited by 229 · cited 2×
“It is consistently ranked as one of the least harmful illicit psychoactive substances (4, 5), despite being among the most highly regulated substances globally.”
BackgroundJones, C. M., Houry, D., Han, B., Baldwin, G., Vivolo‐Kantor, A., & Compton, W. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14688 · Cited by 202
Mechanisms of methamphetamine-induced dopaminergic neurotoxicity
Riddle, E. L., Fleckenstein, A. E., & Hanson, G. R. (2006) · The AAPS Journal · doi:10.1007/bf02854914 · Cited by 199
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · cited 1×
“Studies to-date looking at the impact of serotonergic antidepressants on the intensity of psilocybin effects have demonstrated mixed results (73, 74).”
ResultThe neurobiology of methamphetamine induced psychosis
Hsieh, J. H., Stein, D. J., & Howells, F. M. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00537 · Cited by 178 · cited 1×
“As the neurobiological correlates of primary psychotic disorders and stimulant-induced psychosis are thought to be quite distinct (70), so too may be the psilocybin-related risk for psychosis and stimulant-induced psychosis.”
BackgroundRecent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology
Yu, S., Zhu, L., Shen, Q., Bai, X., & Di, X. (2015) · Behavioural Neurology · doi:10.1155/2015/103969 · Cited by 175
Contingency management for the treatment of methamphetamine use disorder: A systematic review
Brown, H. D., & DeFulio, A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108307 · Cited by 175
Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., Timmermann, C., Nour, M. M., Kaelen, M., Nutt, D., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06187-5 · Cited by 164
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
Crystalline methamphetamine use and methamphetamine‐related harms in Australia
Degenhardt, L., Sara, G., McKetin, R., Roxburgh, A., Dobbins, T., Farrell, M., Burns, L., & Hall, W. D. (2017) · Drug and Alcohol Review · doi:10.1111/dar.12426 · Cited by 159
Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00955 · Cited by 157
The Australian drug harms ranking study
Bonomo, Y., Norman, A., Biondo, S., Bruno, R., Daglish, M., Dawe, S., Egerton-Warburton, D., Karro, J., Kim, C., Lenton, S., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119841569 · Cited by 154
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Linnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 151
Non-pharmacological interventions for methamphetamine use disorder: a systematic review
AshaRani, P., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108060 · Cited by 143
Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis
Cumming, C., Troeung, L., Young, J. T., Kelty, E., & Preen, D. B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.001 · Cited by 131
A systematic review of risk factors for methamphetamine-associated psychosis
Arunogiri, S., Foulds, J., McKetin, R., & Lubman, D. I. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417748750 · Cited by 123 · cited 1×
“Further exclusions might be considered within early proof-ofconcept trials based on additional risk factors for first-break psychosis–such as being under 25 years old, active self-harm, or a history of violent behavior (67, 68)—or endophenotypes for psychotic illness (69).”
BackgroundIudicello, J. E., Woods, S. P., Vigil, O., Cobb Scott, J., Cherner, M., Heaton, R. K., Hampton Atkinson, J., Grant, I., & Ce, T. H. N. R. (2010) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903512637 · Cited by 111
Association of Methamphetamine and Opioid Use With Nonfatal Overdose in Rural Communities
Korthuis, P. T., Cook, R. R., Foot, C. A., Leichtling, G., Tsui, J. I., Stopka, T. J., Leahy, J., Jenkins, W. D., Baker, R., Chan, B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26544 · Cited by 102 · cited 1×
“Polysubstance use is prevalent among people who use methamphetamine (37, 72); those with polysubstance use and greater use severity may stand to benefit most from innovative transdiagnostic treatments.”
BackgroundSelf-citationSpirituality-Based Recovery From Drug Addiction in the Twelve-Step Fellowship of Narcotics Anonymous
Galanter, M., Dermatis, H., Post, S., & Sampson, C. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31828a0265 · Cited by 101 · cited 1×
“Spiritual engagement is a common recovery strategy used by individuals with methamphetamine use disorder (63), and an experience of spiritual awakening among individuals in Narcotics Anonymous (N = 527) was associated with lower rates of drug craving (64).”
BackgroundDoes Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96 · cited 3×
“There is an emerging hypothesis that psychedelic-assisted psychotherapy holds transdiagnostic treatment potential, possibly due to its ability to increase neuronal and mental plasticity (36).”
BackgroundInfluentialThe use of waitlists as control conditions in anxiety disorders research
Patterson, B., Boyle, M. H., Kivlenieks, M., & Van Ameringen, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.08.015 · Cited by 94 · cited 1×
“However, uncertainty remains regarding the optimal treatment for methamphetamine use disorder, treatment-as-usual varies substantially across treatment settings, and use of a waitlist control can present ethical issues among high-risk clinical populations (89).”
BackgroundRapier, R., McKernan, S., & Stauffer, C. S. (2019) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2019.100188 · Cited by 80 · cited 1×
“Methamphetamine use has been inversely associated with perceived social support (54), and the most common barriers to accessing treatment for people with methamphetamine use disorder tend to be psychosocial in nature (15).”
BackgroundSelf-citationCorrelates of Outpatient Drug Treatment Drop-Out Among Methamphetamine Users
Maglione, M., Chao, B., & Anglin, M. D. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400232 · Cited by 75
The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis
Lecomte, T., Dumais, A., Dugré, J. R., & Potvin, S. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.05.033 · Cited by 75
The therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
The serotonin 5-HT2Creceptor and the non-addictive nature of classic hallucinogens
Canal, C. E., & Murnane, K. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116677104 · Cited by 67 · cited 1×
“Psilocybin is a non-addictive classic psychedelic (22, 23) with neuroplasticity-inducing properties (24, 25).”
BackgroundSelf-citationStauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00169 · Cited by 65
Self-citationState of the art in harm reduction psychotherapy: an emerging treatment for substance misuse
Tatarsky, A., & Marlatt, G. A. (2010) · Journal of Clinical Psychology · doi:10.1002/jclp.20672 · Cited by 58
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Fogg, C., Michaels, T. I., de la Salle, S., Jahn, Z. W., & Williams, M. T. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000490 · Cited by 54 · cited 1×
“To explore the utility of this treatment approach for individuals most in need, psychedelic study samples should represent diverse populations and actively address health disparities known to exist within psychedelic therapy research (76).”
BackgroundA review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211008567 · Cited by 51
Baker, A., & Dawe, S. (2005) · Australian Psychologist · doi:10.1080/00050060500094654 · Cited by 50
Stuart, A. M., Baker, A. L., Denham, A. M. J., Lee, N. K., Hall, A., Oldmeadow, C., Dunlop, A., Bowman, J., & McCarter, K. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.09.005 · Cited by 49
The disparate impact of alcohol, methamphetamine, and other drugs on family reunification
Lloyd, M. H., & Akin, B. A. (2014) · Children and Youth Services Review · doi:10.1016/j.childyouth.2014.05.013 · Cited by 44 · cited 1×
“Moreover, people who use methamphetamine consistently demonstrate more challenges in treatment and recovery compared to those using other substances (16, 17).”
BackgroundProebstl, L., Krause, D., Kamp, F., Hager, L., Manz, K. M., Schacht-Jablonowsky, M., Straif, M., Riebschläger, M., Neumann, S., Anne, S., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112599 · Cited by 44
Murnane, K. S., Perrine, S. A., Finton, B. J., Galloway, M. P., Howell, L. L., & Fantegrossi, W. E. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2504-0 · Cited by 43
Self-citationPsychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37 · cited 1×
“Another hypothesized mechanism is psilocybininduced neuroplasticity (49).”
Methamphetamine exposures reported to United States poison control centers, 2000–2019
Chen, T., Spiller, H. A., Badeti, J., Funk, A. R., Zhu, M., & Smith, G. A. (2021) · Clinical Toxicology · doi:10.1080/15563650.2020.1861287 · Cited by 30
Does Posttraumatic Stress Disorder Affect Post-Treatment Methamphetamine Use?
Glasner, S. V., Mooney, L. J., Ang, A., Hillhouse, M. P., Rawson, R. A., & Methamphetamine Treatment Project C (2013) · Journal of Dual Diagnosis · doi:10.1080/15504263.2013.779157 · Cited by 20 · cited 1×
“There are no adequate treatments for dual diagnoses of methamphetamine use disorder and psychiatric illness; although such comorbidity adversely affects methamphetamine treatment outcomes (39, 40), and treatments of higher intensity are recommended (41).”
BackgroundConceptualizing Social Recovery: Recovery Routes of Methamphetamine Users
Boeri, M. W., Gibson, D., & Boshears, P. (2014) · doi:10.21428/88de04a1.ce2a8386 · Cited by 20
Effects of Naltrexone on Large-Scale Network Interactions in Methamphetamine Use Disorder
Kohno, M., Morales, A. M., Dennis, L. E., McCready, H. D., Hoffman, W. F., & Korthuis, P. T. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00603 · Cited by 19 · cited 1×
“Indeed, decoupling of the default mode network through other pharmaceutical interventions is associated with reduction in risky decision-making among patients with methamphetamine use disorder (48).”
BackgroundSelf-citationJaehne, E. J., Ameti, D., Paiva, T., & van den Buuse, M. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00061 · Cited by 18
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Blakey, R., Ranlund, S. M., Zartaloudi, E., Cahn, W., Calafato, S., Colizzi, M., Crespo‐Facorro, B., Daniel, C., Díez, Á., Forti, M. D., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717002860 · Cited by 17 · cited 1×
“Further exclusions might be considered within early proof-ofconcept trials based on additional risk factors for first-break psychosis–such as being under 25 years old, active self-harm, or a history of violent behavior (67, 68)—or endophenotypes for psychotic illness (69).”
BackgroundContinuing Increase in Stimulant Dependence – Time to Implement Medical Treatment
Bisaga, A. M., Tardelli, V. S., Gerra, G., Busse, A., Campello, G., Kashino, W., Sáenz, E., & Fidalgo, T. M. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221083505 · Cited by 16 · cited 1×
“Innovative and effective treatments are urgently needed to address the mounting methamphetamine epidemic (20, 21).”
BackgroundOxytocin, a Novel Treatment for Methamphetamine Use Disorder
Edinoff, A. N., Thompson, E., Merriman, C. E., Alvarez, M. R., Alpaugh, E. S., Cornett, E. M., Murnane, K. S., Kozinn, R. L., Shah-Bruce, M., Kaye, A. M., et al. (2022) · Neurology International · doi:10.3390/neurolint14010015 · Cited by 15
Self-citationSepulveda, M., Manning, E. E., Gogos, A., Hale, M. W., & van den Buuse, M. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147428 · Cited by 14
Tuv, S. S., Bergh, M. S., Andersen, J. M., Steinsland, S., Vindenes, V., Baumann, M. H., Huestis, M. A., & Bogen, I. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112002 · Cited by 14 · cited 1×
“There are putative concerns specific to methamphetamine; the predominant mechanism of action of methamphetamine is to elevate the concentration of the monoamines dopamine and norepinephrine within the synaptic cleft through substrate-based release and interrupted reuptake (77, 78).”
BackgroundHuang, W.-S., Chen, G., Tsai, T., Cheng, C.-Y., Shiue, C., Ma, K., & Yeh, S. H. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0557-y · Cited by 13
Tsai, T.-Y., Wang, T., Tseng, H., Chen, K. C., Chiu, C., Chen, P. S., & Yang, Y. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-11901-6 · Cited by 12 · cited 1×
“Social isolation and loneliness are common among methamphetamine users and associated with poor methamphetamine treatment outcomes (55, 56).”
BackgroundLarge, M., Dall, B., & Nielssen, O. B. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413489176 · Cited by 10 · cited 1×
“Further exclusions might be considered within early proof-ofconcept trials based on additional risk factors for first-break psychosis–such as being under 25 years old, active self-harm, or a history of violent behavior (67, 68)—or endophenotypes for psychotic illness (69).”
BackgroundReview of methamphetamine use among Aboriginal and Torres Strait Islander people
Snijder, M., & Kershaw, S. (2019) · Cited by 9
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1 · cited 1×
“For a treatment approach that may be associated with changes across a wide range of clinical symptoms, psilocybin-assisted psychotherapy studies should measure diverse secondary clinical outcomes such as motivation and self-efficacy for change (85), drug craving, symptoms of comorbid disorders (e.”
BackgroundSerotonergic antidepressant use is associated with weaker psilocybin effectsPreprint
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2022) · doi:10.31234/osf.io/2zys9 · Cited by 1
Research works printed but not linked: 2
- Dianne, 2021, S.854 - Methamphetamine response act of 2021.
- Hendricks, 2019, Psilocybin treatment of cocaine use disorder.
Cited by
Novel therapeutics in development for the treatment of stimulant-use disorder
Young, E. J., Radnai, L., Prikhodko, V., & Miller, C. A. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102898 · Cited by 16
Sharma, P., Sawaya, M. F., Dumitrescu, A. M., Kolluru, G. K., Schmoutz, C. D., Salinas, A. G., Cannon, C. E., Kumbhare, D., Korneeva, N. L., Vest, M. F., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00770 · Cited by 15
Self-citationBrett, J., Knock, E., Watson, K., Albert, S., Siefried, K. J., & Guss, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1490907 · Cited by 7
Self-citationKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Self-citationExploring the therapeutic potential of psychedelics in treating substance use disorders
Li, Y., Li, H., Wang, H., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03168-w · Cited by 8
“Research needs to explore the potential of these compounds across different types of SUDs, including those with limited effective treatments, such as methamphetamine [79] and cocaine addiction.”
Metadata
- Authors
- Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S.
- Affiliations
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Oregon Health & Science University (US)
- Monash University (AU)
- Louisiana State University (US)
- University of Wisconsin–Madison (US)
- Corresponding author
- Stauffer, Christopher S.
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-03-14
- Volume
- 14
- Pages
- 1123424-1123424
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10043240
- OpenAlex
- W4324145541
- Cited by
- 16
- References
- 87
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 2
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- psilocybin-assisted therapy, methamphetamine dependence, psychedelic therapy, addiction treatment, relapse, clinical trial design, treatment implementation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.